Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1

Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is... Cell division cycle 7 (Cdc7) plays important roles in the regulation of the initiation of DNA replication throughout S phase. Whether inhibition of Cdc7 has a direct antitumour effect in oral squamous cell carcinoma (OSCC) remains unclear. In this study, XL413, a novel Cdc7 inhibitor, markedly inhibited the viability of OSCC cells but not that of non-tumour primary cells. There was a synergistic effect between XL413 and DNA-damaging agents (e.g. cisplatin and 5-fluorouracil) on OSCC in vitro and in vivo. Moreover, XL413 exhibited a notable antitumour effect on OSCC patients with high Cdc7 expression in mini patient-derived xenografts model. The proliferation was significantly inhibited in OSCC cells after Cdc7 silencing. Cdc7 knockdown significantly induced apoptosis in OSCC cell lines. Furthermore, we demonstrated that Cdc7 was overexpressed and transcriptionally regulated by E2F1 in OSCC by using chromatin immunoprecipitation and luciferase assays. Our results reveal that XL413 has an excellent antitumour effect in OSCC. Importantly, it does not inhibit the proliferation of non-tumour cells. These findings suggest that the overexpression of Cdc7 promotes progression in OSCC and that inhibition of Cdc7 is a very promising therapy for OSCC patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Molecular Medicine Springer Journals

Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1

Download PDF
13 pages

Loading next page...
 
/lp/springer_journal/cell-division-cycle-7-is-a-potential-therapeutic-target-in-oral-jfmJr7Bp62
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Molecular Medicine; Human Genetics; Internal Medicine
ISSN
0946-2716
eISSN
1432-1440
DOI
10.1007/s00109-018-1636-7
Publisher site
See Article on Publisher Site

Abstract

Cell division cycle 7 (Cdc7) plays important roles in the regulation of the initiation of DNA replication throughout S phase. Whether inhibition of Cdc7 has a direct antitumour effect in oral squamous cell carcinoma (OSCC) remains unclear. In this study, XL413, a novel Cdc7 inhibitor, markedly inhibited the viability of OSCC cells but not that of non-tumour primary cells. There was a synergistic effect between XL413 and DNA-damaging agents (e.g. cisplatin and 5-fluorouracil) on OSCC in vitro and in vivo. Moreover, XL413 exhibited a notable antitumour effect on OSCC patients with high Cdc7 expression in mini patient-derived xenografts model. The proliferation was significantly inhibited in OSCC cells after Cdc7 silencing. Cdc7 knockdown significantly induced apoptosis in OSCC cell lines. Furthermore, we demonstrated that Cdc7 was overexpressed and transcriptionally regulated by E2F1 in OSCC by using chromatin immunoprecipitation and luciferase assays. Our results reveal that XL413 has an excellent antitumour effect in OSCC. Importantly, it does not inhibit the proliferation of non-tumour cells. These findings suggest that the overexpression of Cdc7 promotes progression in OSCC and that inhibition of Cdc7 is a very promising therapy for OSCC patients.

Journal

Journal of Molecular Medicine – Springer Journals

Published: Apr 30, 2018

References

  • Oral cavity carcinoma: current management, controversies, and future directions
    Chinn, SB; Myers, JN
  • Nucleotide deficiency promotes genomic instability in early stages of cancer development
    Bester, A; Roniger, M; Oren, Y; Im, M; Sarni, D; Chaoat, M; Bensimon, A; Zamir, G; Shewach, D; Kerem, B
  • Exploiting replicative stress to treat cancer
    Dobbelstein, M; Sorensen, CS
  • A novel growth- and cell cycle-regulated protein, ASK, activates human Cdc7-related kinase and is essential for G1/S transition in mammalian cells
    Kumagai, H; Sato, N; Yamada, M; Mahony, D; Seghezzi, W; Lees, E; Arai, K; Masai, H
  • SRSF1 prevents DNA damage and promotes tumorigenesis through regulation of DBF4B pre-mRNA splicing
    Chen, L; Luo, C; Shen, L; Liu, Y; Wang, Q; Zhang, C; Guo, R; Zhang, Y; Xie, Z; Wei, N; Wu, W; Han, J; Feng, Y
  • Regulation and roles of Cdc7 kinase under replication stress
    Yamada, M; Masai, H; Bartek, J
  • A 63-base pair DNA segment containing an Sp1 site but not a canonical E2F site can confer growth-dependent and E2F-mediated transcriptional stimulation of the human ASK gene encoding the regulatory subunit for human Cdc7-related kinase
    Yamada, M; Sato, N; Taniyama, C; Ohtani, K; Arai, K; Masai, H
  • Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation
    Bonte, D; Lindvall, C; Liu, H; Dykema, K; Furge, K; Weinreich, M
  • Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers
    Rodriguez-Acebes, S; Proctor, I; Loddo, M; Wollenschlaeger, A; Rashid, M; Falzon, M; Prevost, AT; Sainsbury, R; Stoeber, K; Williams, GH
  • Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma
    Kulkarni, AA; Kingsbury, SR; Tudzarova, S; Hong, HK; Loddo, M; Rashid, M; Rodriguez-Acebes, S; Prevost, AT; Ledermann, JA; Stoeber, K; Williams, GH
  • High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma
    Hou, Y; Wang, HQ; Ba, Y
  • Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents
    Cheng, AN; Jiang, SS; Fan, CC; Lo, YK; Kuo, CY; Chen, CH; Liu, YL; Lee, CC; Chen, WS; Huang, TS; Wang, TY; Lee, AY
  • Targeting cell division cycle 7 kinase: a new approach for cancer therapy
    Montagnoli, A; Moll, J; Colotta, F
  • Association between gene expression profile and tumor invasion in oral squamous cell carcinoma
    Toruner, GA; Ulger, C; Alkan, M; Galante, AT; Rinaggio, J; Wilk, R; Tian, B; Soteropoulos, P; Hameed, MR; Schwalb, MN; Dermody, JJ
  • Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation
    Yap, L; Jenei, V; Robinson, C; Moutasim, K; Benn, T; Threadgold, S; Lopes, V; Wei, W; Thomas, G; Paterson, I
  • Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
    Gao, J; Aksoy, B; Dogrusoz, U; Dresdner, G; Gross, B; Sumer, S; Sun, Y; Jacobsen, A; Sinha, R; Larsson, E; Cerami, E; Sander, C; Schultz, N
  • The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
    Cerami, E; Gao, J; Dogrusoz, U; Gross, B; Sumer, S; Aksoy, B; Jacobsen, A; Byrne, C; Heuer, M; Larsson, E; Antipin, Y; Reva, B; Goldberg, A; Sander, C; Schultz, N
  • XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-beta1-stimulated C3H10T1/2 cells via Smad2/4
    Jin, SF; Ma, HL; Liu, ZL; Fu, ST; Zhang, CP; He, Y
  • Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma
    Ma, HL; Jin, SF; Ju, WT; Fu, Y; Tu, YY; Wang, LZ; Jiang, L; Zhang, ZY; Zhong, LP
  • Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma
    Ma, H; Jin, S; Yang, W; Zhou, G; Zhao, M; Fang, S; Zhang, Z; Hu, J
  • Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo
    Bruzzese, F; Gennaro, E; Avallone, A; Pepe, S; Arra, C; Caraglia, M; Tagliaferri, P; Budillon, A
  • Interferon-alpha promotes the expression of cancer stem cell markers in oral squamous cell carcinoma
    Ma, H; Jin, S; Yang, W; Tian, Z; Liu, S; Wang, Y; Zhou, G; Zhao, M; Gvetadze, S; Zhang, Z; Hu, J
  • Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis
    Tanaka, C; Uzawa, K; Shibahara, T; Yokoe, H; Noma, H; Tanzawa, H
  • Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways
    Zhang, G; Chen, T; Hargreaves, R; Sur, C; Williams, D
  • Discovery of XL413, a potent and selective CDC7 inhibitor
    Koltun, ES; Tsuhako, AL; Brown, DS; Aay, N; Arcalas, A; Chan, V; Du, H; Engst, S; Ferguson, K; Franzini, M; Galan, A; Holst, CR; Huang, P; Kane, B; Kim, MH; Li, J; Markby, D; Mohan, M; Noson, K; Plonowski, A; Richards, SJ; Robertson, S; Shaw, K; Stott, G; Stout, TJ; Young, J; Yu, P; Zaharia, CA; Zhang, W; Zhou, P; Nuss, JM; Xu, W; Kearney, PC
  • DNA replication dynamics and cellular responses to ATP competitive CDC7 kinase inhibitors
    Rainey, M; Quachthithu, H; Gaboriau, D; Santocanale, C
  • Dual inhibition of Cdc7 and Cdk9 by PHA-767491 suppresses hepatocarcinoma synergistically with 5-fluorouracil
    Li, W; Zhao, XL; Shang, SQ; Shen, HQ; Chen, X
  • Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness
    Erbayraktar, Z; Alural, B; Erbayraktar, RS; Erkan, EP
  • A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
    Montagnoli, A; Valsasina, B; Croci, V; Menichincheri, M; Rainoldi, S; Marchesi, V; Tibolla, M; Tenca, P; Brotherton, D; Albanese, C; Patton, V; Alzani, R; Ciavolella, A; Sola, F; Molinari, A; Volpi, D; Avanzi, N; Fiorentini, F; Cattoni, M; Healy, S; Ballinari, D; Pesenti, E; Isacchi, A; Moll, J; Bensimon, A; Vanotti, E; Santocanale, C
  • Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells
    Natoni, A; Murillo, LS; Kliszczak, AE; Catherwood, MA; Montagnoli, A; Samali, A; O’Dwyer, M; Santocanale, C
  • Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication
    Jiang, W; McDonald, D; Hope, TJ; Hunter, T
  • Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells
    Montagnoli, A; Tenca, P; Sola, F; Carpani, D; Brotherton, D; Albanese, C; Santocanale, C
  • Molecular architecture of the DNA replication origin activation checkpoint
    Tudzarova, S; Trotter, M; Wollenschlaeger, A; Mulvey, C; Godovac-Zimmermann, J; Williams, G; Stoeber, K
  • Patient-derived xenografts for individualized care in advanced sarcoma
    Stebbing, J; Paz, K; Schwartz, G; Wexler, L; Maki, R; Pollock, R; Morris, R; Cohen, R; Shankar, A; Blackman, G; Harding, V; Vasquez, D; Krell, J; Zacharoulis, S; Ciznadija, D; Katz, A; Sidransky, D
  • Translational value of mouse models in oncology drug development
    Gould, SE; Junttila, MR; Sauvage, FJ
  • CDC7/DBF4 functions in the translesion synthesis branch of the RAD6 epistasis group in Saccharomyces cerevisiae
    Pessoa-Brandão, L; Sclafani, R
  • DDK promotes tumor chemoresistance and survival via multiple pathways
    Sasi, N; Bhutkar, A; Lanning, N; MacKeigan, J; Weinreich, M